Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?
Jean-François Dhainaut,Olivier Blin,Florence Herry,Sylvain Benito,Pascal Bilbault,Maxime Cauterman,Florence Favrel-Feuillade,Stéphanie Fazi-Leblanc,Caroline Germain,Clément Goehrs,Cécile Grosskopf,Benoit Labarthe,Philippe Lechat,Corneliu Malciu,Pierre Marquet,Corinne Miceli-Richard,Olivier Peyret,Revital Rattenbach,Edouard de Saint-Exupéry
DOI: https://doi.org/10.1016/j.therap.2019.11.010
IF: 3.367
2020-01-01
Therapies
Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><p>Although France has numerous assets in the realm of health care, such as the excellence of its research teams, the reputation of its healthcare system, and the presence of many startups, all of which are necessary to become a leader in innovation, it also has combined cultural and regulatory barriers that limit the flexibility and efficiency of interactions between companies/startups and public health institutions. Therefore, the aim of the roundtable discussion was to optimize the interface between those businesses and institutions. Several institutions have successfully implemented teams and procedures which aim to facilitate this interface, with regard to assessments of technology, services provided, the transfer of biological material, R&D collaboration, and licensing agreements. However, there is still a notable absence of entrepreneurial culture among hospital and academic research practitioners; their training regarding innovation remains insufficient and business-related value-creation is non-existent in their career evolution.</p><p>Pharmaceutical companies, and particularly startups, often lack knowledge about hospital environments and their constraints. As a result, the recommendations of the roundtable participants are as follows: (1) promote reciprocal acculturation between public health institutions and startups through multidisciplinary training in innovation, promoting project development and staff recognition within the institution, and improving pharmaceutical companies' understanding regarding the health care system; (2) provide those involved with means and resources dedicated to innovation by reserving time for innovation at work, securing the status of the staff involved, and aiding in the search for funding; (3) develop and use standard methodologies and tools; and (4) co-design and co-construct innovative health solutions, encouraging the emergence of participatory and interdisciplinary creative spaces. All of these recommendations should help to make the interface between startups/companies and public health institutions more fluid and attractive for those in the health sector.</p>